Medi Assist Healthcare Services (NSE:MEDIASSIST) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:MEDIASSIST Medi Assist Healthcare Services Ltd NSE:MEDIASSIST
46 GF Score
Price ₹374.70
! 4 Warning Signs
View Full Analysis

What is Medi Assist Healthcare Services Research & Development?

Medi Assist Healthcare Services NSE:MEDIASSIST -0.33% 46 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:MEDIASSIST with a GF Score™ of 46/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medi Assist Healthcare Services's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Medi Assist Healthcare Services  (NSE:MEDIASSIST) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medi Assist Healthcare Services Research & Development Related Terms

Medi Assist Healthcare Services Research & Development Historical Data

* Premium members only.

The historical data trend for Medi Assist Healthcare Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medi Assist Healthcare Services Research & Development Chart

Medi Assist Healthcare Services Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Medi Assist Healthcare Services Quarterly Data
Mar21 Mar22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MEDIASSIST
46GF Score
Medi Assist Healthcare Services Ltd NSE:MEDIASSIST
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medi Assist Healthcare Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Medi Assist Healthcare Services (NSE:MEDIASSIST) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medi Assist Healthcare Services and its competitors.
Is Medi Assist Healthcare Services' Research & Development too high?
Medi Assist Healthcare Services' current Research & Development is ₹0 Mil. Overall, Medi Assist Healthcare Services has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Medi Assist Healthcare Services' Research & Development compare to UNH and CVS?
Medi Assist Healthcare Services' Research & Development of ₹0 Mil can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Plans company?
A good Research & Development depends on the Healthcare Plans industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medi Assist Healthcare Services and its competitors. Medi Assist Healthcare Services's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medi Assist Healthcare Services stock overvalued right now?
Medi Assist Healthcare Services (NSE:MEDIASSIST) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Medi Assist Healthcare Services' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medi Assist Healthcare Services (NSE:MEDIASSIST), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medi Assist Healthcare Services Business Description

Other Exchanges 544088:India
Address 4/1 Bannerghatta Road, Tower D, 4th floor, IBC Knowledge Park, Bengaluru, KA, IND, 560029
Medi Assist Healthcare Services Ltd is a HealthTech and InsurTech company focused on administering health benefits across employers, retail members, and public health schemes. Its clients are insurance companies and also serve as an intermediary between (a) general and health insurance companies and the insured members, (b) insurance companies and healthcare providers (such as hospitals), and (c) the Government and beneficiaries of public health schemes. The company derives income by providing health management services, software subscriptions, software license services, consultancy services, and other allied services pertaining to the healthcare and health insurance sectors. It also offers business support services and other technical services.
46GF Score

Get the complete analysis for NSE:MEDIASSIST

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹374.70
Price